Talea Group (TALEA) Fair Value & Analysis
Healthcare · IT · Market cap €40.7M
Fair value as of: Jun 25, 2026
Analysis
Talea Group (TALEA) currently trades at €4.80, while our model-based Fair Value estimate is €1.35 — implying the stock looks roughly 71.9% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Talea Group S.p.A. operates as an e-retailer of health, wellness, and beauty products in Italy. It operates through two segments: Consumers Area and Industrial Area. The Consumer Area segment offers cosmetics; hair products; skincare; make up and fragrances; supplements/dietary products; over-the-counter medicines; medical devices; electromedical equipment; hygiene and wellness; mother- and child-care; homeopathic and herbal care products; healthcare products; orthopaedic and health aids; and pet care and nutrition products under the Farmaè, Amicafarmacia, Farmaeurope, Beautyè, and Sanort brand names. Its Industrial Area segment provides digital communication and marketing services under the Valnan brand, as well as manages an ecosystem of digital opportunities for companies through consulting, data analysis, creativity, digital marketing, and data economy services under the Talea Media brand. The company was formerly known as Farmaè S.p.A. and changed its name to Talea Group S.p.A.…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Talea Group (TALEA) undervalued?
What is the fair value of TALEA?
What is the quality score of TALEA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.